SPI Medical Imaging: Brainomix Study Demonstrates the Power of Pharma Partnerships for AI

Brainomix recently published a study in the peer-reviewed journal ‘American Journal of Respiratory and Critical Care Medicine’, resulting from a research collaboration with UK biopharmaceutical company AstraZeneca.

The study, which analysed AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF), showed that Brainomix e-Lung, an AI-enabled automated CT processing software, stratifies patients at risk of IPF progression, outperforming standard measures, and demonstrating e-Lung’s potential role in improving efficiency of future clinical trials.

The completion of the study has considerable potential benefits for both Brainomix and AstraZeneca. It may also be a compelling example for AI vendors weighing the advantages of entering into pharmaceutical partnerships.